Cellebrite DI [CLBT] vs Oracle [ORCL] Detailed Stock Comparison
Cellebrite DI
NASDAQ
Loading...
Oracle
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Cellebrite DI wins in 7 metrics, Oracle wins in 12 metrics, with 0 ties. Oracle appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Cellebrite DI | Oracle | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 69.09 | 53.72 | Oracle |
| Price-to-Book Ratio | 9.55 | 32.00 | Cellebrite DI |
| Debt-to-Equity Ratio | 5.47 | 519.59 | Cellebrite DI |
| PEG Ratio | 39.88 | 32.56 | Oracle |
| EV/EBITDA | 46.15 | 32.07 | Oracle |
| Profit Margin (TTM) | -34.56% | 21.68% | Oracle |
| Operating Margin (TTM) | 14.58% | 32.48% | Oracle |
| EBITDA Margin (TTM) | 14.58% | 32.48% | Oracle |
| Return on Equity | -81.98% | 82.38% | Oracle |
| Return on Assets (TTM) | 5.95% | 7.26% | Oracle |
| Free Cash Flow (TTM) | $121.56M | $-394.00M | Cellebrite DI |
| Dividend Yield | N/A | 0.81% | N/A |
| 1-Year Return | -6.01% | 69.82% | Oracle |
| Price-to-Sales Ratio (TTM) | 8.93 | 11.41 | Cellebrite DI |
| Enterprise Value | $3.44B | $753.17B | Oracle |
| EV/Revenue Ratio | 7.88 | 13.12 | Cellebrite DI |
| Gross Profit Margin (TTM) | 84.39% | 70.19% | Cellebrite DI |
| Revenue per Share (TTM) | $2 | $21 | Oracle |
| Earnings per Share (Diluted) | $-0.72 | $4.34 | Oracle |
| Beta (Stock Volatility) | 1.27 | 1.43 | Cellebrite DI |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Cellebrite DI vs Oracle Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Cellebrite DI | 1.26% | 3.27% | 12.97% | -3.59% | -14.99% | -25.62% |
| Oracle | 1.38% | -4.80% | -0.73% | 50.26% | 39.07% | 42.37% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Cellebrite DI | -6.01% | 235.83% | 66.87% | 66.87% | 66.87% | 66.87% |
| Oracle | 69.82% | 216.64% | 308.38% | 530.99% | 950.07% | 1,732.33% |
Performance & Financial Health Analysis: Cellebrite DI vs Oracle
| Metric | CLBT | ORCL |
|---|---|---|
| Market Information | ||
| Market Cap | $3.90B | $654.91B |
| Market Cap Category | Mid cap | Mega cap |
| 10 Day Avg. Volume | 3,165,587 | 10,558,180 |
| 90 Day Avg. Volume | 2,043,326 | 10,423,740 |
| Last Close | $16.11 | $236.37 |
| 52 Week Range | $13.10 - $26.30 | $118.86 - $260.87 |
| % from 52W High | -38.75% | -9.39% |
| All-Time High | $26.30 (Feb 03, 2025) | $260.87 (Jul 31, 2025) |
| % from All-Time High | -38.75% | -9.39% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.18% | 0.11% |
| Quarterly Earnings Growth | 0.18% | 0.09% |
| Financial Health | ||
| Profit Margin (TTM) | -0.35% | 0.22% |
| Operating Margin (TTM) | 0.15% | 0.32% |
| Return on Equity (TTM) | -0.82% | 0.82% |
| Debt to Equity (MRQ) | 5.47 | 519.59 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.67 | $7.29 |
| Cash per Share (MRQ) | $1.93 | $3.99 |
| Operating Cash Flow (TTM) | $161.08M | $20.82B |
| Levered Free Cash Flow (TTM) | $122.92M | $678.00M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.81% |
| Last 12-Month Dividend | N/A | $1.70 |
Valuation & Enterprise Metrics Analysis: Cellebrite DI vs Oracle
| Metric | CLBT | ORCL |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 69.09 | 53.72 |
| Forward P/E | 39.88 | 32.56 |
| PEG Ratio | 39.88 | 32.56 |
| Price to Sales (TTM) | 8.93 | 11.41 |
| Price to Book (MRQ) | 9.55 | 32.00 |
| Market Capitalization | ||
| Market Capitalization | $3.90B | $654.91B |
| Enterprise Value | $3.44B | $753.17B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.88 | 13.12 |
| Enterprise to EBITDA | 46.15 | 32.07 |
| Risk & Other Metrics | ||
| Beta | 1.27 | 1.43 |
| Book Value per Share (MRQ) | $1.67 | $7.29 |
Financial Statements Comparison: Cellebrite DI vs Oracle
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CLBT | ORCL |
|---|---|---|
| Revenue/Sales | $113.28M | $15.90B |
| Cost of Goods Sold | $17.68M | $4.74B |
| Gross Profit | $95.60M | $11.16B |
| Research & Development | $28.61M | $2.65B |
| Operating Income (EBIT) | $14.42M | $5.19B |
| EBITDA | $17.01M | $7.00B |
| Pre-Tax Income | $20.79M | $4.15B |
| Income Tax | $1.32M | $725.00M |
| Net Income (Profit) | $19.48M | $3.43B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CLBT | ORCL |
|---|---|---|
| Cash & Equivalents | $90.48M | $10.79B |
| Total Current Assets | $523.48M | $24.58B |
| Total Current Liabilities | $287.80M | $32.64B |
| Long-Term Debt | $6.39M | $96.83B |
| Total Shareholders Equity | $363.49M | $20.97B |
| Retained Earnings | $-147.46M | $-15.48B |
| Property, Plant & Equipment | $28.03M | $0 |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CLBT | ORCL |
|---|---|---|
| Operating Cash Flow | $28.07M | $5.93B |
| Capital Expenditures | $-2.34M | N/A |
| Free Cash Flow | $18.54M | $-2.92B |
| Debt Repayment | N/A | $-6.07B |
| Common Stock Repurchase | N/A | $-150.00M |
Short Interest & Institutional Ownership Analysis
| Metric | CLBT | ORCL |
|---|---|---|
| Shares Short | 3.63M | 20.69M |
| Short Ratio | 2.40 | 1.58 |
| Short % of Float | 0.03% | 0.01% |
| Average Daily Volume (10 Day) | 3,165,587 | 10,558,180 |
| Average Daily Volume (90 Day) | 2,043,326 | 10,423,740 |
| Shares Outstanding | 234.52M | 2.81B |
| Float Shares | 112.43M | 1.64B |
| % Held by Insiders | 0.45% | 0.42% |
| % Held by Institutions | 0.50% | 0.45% |
Dividend Analysis & Yield Comparison: Cellebrite DI vs Oracle
| Metric | CLBT | ORCL |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.70 |
| Last 12-Month Dividend Yield | N/A | 0.81% |
| 3-Year Avg Annual Dividend | N/A | $1.55 |
| 3-Year Avg Dividend Yield | N/A | 0.36% |
| 3-Year Total Dividends | N/A | $4.66 |
| Ex-Dividend Date | N/A | Apr 10, 2025 |